论文部分内容阅读
结合对于卵巢癌免疫诊断可能性的探索工作,使用双相琼脂扩散法、对流免疫电泳法、电泳免疫扩散法,我们对各型恶性卵巢瘤病人血清、腹水、肿瘤囊液及瘤组织提取液中的AFP进行了检测。在病理学证实的59例恶性卵巢瘤病人血清中,有11例能检出AFP,阳性率占18.6％按肿瘤的病理组织学类型分类统计AFP阳性率为:恶性畸胞瘤66.7％(4/6),浆液性囊腺癌20.0％(4/20),粘液性囊腺癌1/13,未定型的腺癌1/7,颗粒细胞癌1/4。其它无性细胞瘤(0/2)、卵泡膜细胞瘤(0/2)、卵巢鳞状上皮癌(0/1)、卵巢胶样癌(0/1)均未检得。在血清阳性病例中,其肿瘤囊液、肿瘤提取液及腹水中亦能测出AFP的存在。定量测定结果表明,上述各样品中每毫升的AFP含量在数十至200微克之间。 用对流免疫电泳法,2/3的卵巢恶性畸胎瘤病人血中可检出AFP。就这种AFP的产生部位,与病情及恶变成分的关系等问题进行了分析讨论。 有些没有肝转移的卵巢腺癌病人亦可检得AFP,应引起注意。
Combined with the research on the possibility of immune diagnosis of ovarian cancer, we used two-phase agar diffusion method, convective immuno-electrophoresis method and electrophoresis-based immunodiffusion method to detect the possibility of immune diagnosis in ovarian cancer patients, including serum, ascites, tumor cyst and tumor tissue extracts The AFP was tested. Among the 59 pathologically confirmed malignant ovarian tumor patients, 11 cases were positive for AFP, accounting for 18.6%. According to the histopathological classification of tumors, the positive rate of AFP was 66.7% (4 / 6), serous cystadenocarcinoma 20.0% (4/20), mucinous cystadenocarcinoma 1/13, unfixed adenocarcinoma 1/7, and granulosa cell carcinoma 1/4. None of the other dysgerminoma (0/2), theca cell tumor (0/2), ovarian squamous cell carcinoma (0/1), ovariectomized carcinoma (0/1) were not detected. Serum positive cases, the tumor cyst fluid, tumor extract and ascites also can detect the presence of AFP. The quantitative determination results show that the AFP content per ml in each of the above samples is between several tens to 200 micrograms. With convective immuno-electrophoresis, 2/3 of ovarian malignant teratoma patients can be detected in the blood of AFP. On the production of AFP site, and the relationship between the disease and malignant components and other issues were analyzed and discussed. Some patients with ovarian adenocarcinoma who do not have liver metastases may also be tested for AFP and should pay attention.